Several studies have addressed the role of IL-2 administration on the frequency and function of human Treg cells in cancer patients and demonstrated that treatment with recombinant IL-2 induces an expansion of Treg cells in peripheral blood, thereby interfering with efficient anti-tumor immune responses [37], [38], [39], [40], [41], [42], [43]. This evidence concerns the gene IL2 and neoplasm.